ArticleImmunity, inflammation and disease2026
Dysregulation of the TLR4/MyD88/NF-κB Signaling Pathway and Pro-Inflammatory Cytokines in First-Episode Major Depressive Disorder: A Cross-Sectional Case-Control Study.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionInflammation is increasingly recognized as a key contributor to the development and progression of major depressive disorder (MDD). This case-control study aims to assess the expression of inflammatory pathway components (TRIF, MyD88, NF-κB) and serum levels of TNF-α and IL-6 in remitted and untreated MDD patients compared to healthy controls.
methodsThis study included 150 participants: 50 newly diagnosed and untreated MDD patients, 50 MDD patients who achieved complete clinical remission following at least 8 weeks of continuous TCA treatment (TCA remitters), and 50 matched healthy controls. MDD diagnosis was based on DSM-V criteria and Beck Depression Inventory (BDI). Peripheral blood samples were collected to isolate serum and PBMCs. mRNA expression of NF-κB, TRIF, and MyD88 was quantified by qRT-PCR, while serum levels of TNF-α and IL-6 were measured using ELISA. Data were analyzed using one-way ANOVA with Tukey's post hoc test, considering p < 0.05 as statistically significant.
resultsNo significant differences were found in age or gender among the three groups, confirming demographic comparability. BDI scores were markedly higher in both untreated and remitted MDD patients compared to controls, with untreated patients showing the most severe symptoms. Gene expression analysis revealed a significant upregulation of MYD88 (~5-fold) and NF-κB (~2.5-fold) in untreated MDD patients compared to controls (p < 0.001); treated patients also showed higher expression, though to a lesser extent. TRIF expression was higher in treated patients, but not significantly. Serum levels of TNF-α and IL-6 were significantly higher in untreated MDD patients versus controls (p < 0.001); IL-6 and TNF-α levels were also higher in treated patients but significantly lower than in the untreated group.
conclusionThe results support the hypothesis of a link between immune dysregulation and MDD. However, further human studies are necessary to validate the findings of the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.